Dapagliflozin: all 489 studies that test it
Page 5 of 5. Open to participants first (118), then studies with results posted, then the rest; newest registration first within each.
- Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.CompletedNCT03970044Phase 4
- Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.Status unknownNCT03961659Not applicable
- Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin TherapyCompletedNCT03959501Phase 4
- SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney DiseaseCompletedNCT03919656Phase 4
- Triple Therapy in T1DMActive, not recruitingNCT03899402Phase 2/3
- Effect of Dapagliflozin on Nighttime Blood Pressure in Type 2 DiabetesStatus unknownNCT03887416Phase 4
- Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment TrialCompletedNCT03871621Phase 4
- Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed ConditionStatus unknownNCT03849339Phase 1
- Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 in Healthy AdultsStatus unknownNCT03849261Phase 1
- Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male AdultsCompletedNCT03766724Phase 1
- The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-387 Under Fed ConditionCompletedNCT03738449Phase 1
- Dapagliflozin Efficacy and Action in NASHCompletedNCT03723252Phase 3
- Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate OxidationCompletedNCT03721874Phase 4
- Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.CompletedNCT03714594Phase 2
- Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in ObesityStatus unknownNCT03710460Phase 4
- Dapagliflozin Effects on HypoglycemiaCompletedNCT03704818Phase 1
- Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial InfarctionStatus unknownNCT03658031Phase 3
- Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 in Healthy AdultsStatus unknownNCT03646799Phase 1
- Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/SaxagliptinTerminatedNCT03608358Phase 3
- Dapagliflozin on Blood Pressure Variability and Ambulatory Arterial Stiffness Index in HypertensionStatus unknownNCT03592667Phase 4
- Gemigliptin, Dapagliflozin, Empagliflozin DDI StudyStatus unknownNCT03565458Phase 1
- Effect of Dapagliflozin on IAH in T1DMCompletedNCT03556033Phase 2
- Dapagliflozin During Exercise for the PrevenTion of HypoglycaemiaTerminatedNCT03537131Phase 2
- Dapagliflozin Effect on Erythropoiesis and Physical FitnessWithdrawnNCT03423355Phase 4
- The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant PatientsTerminatedNCT03419624Phase 3
- Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery DiseaseStatus unknownNCT03398577Phase 4
- Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 DiabetesStatus unknownNCT03377335Phase 4
- DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2CompletedNCT03361098Phase 4
- A Phase IV Study in Drug-Naive Patients With T2DM in ChinaTerminatedNCT03344341Phase 4
- Effects of SGLT2 Inhibition on Myocardial Insulin SensitivityCompletedNCT03313752Phase 3
- Evaluate the Effects of Dapagliflozin in Patients With Type 2 DiabetesCompletedNCT03269058Phase 4
- Effects of DPP4 Inhibitor Versus SGLT2 InhibitorCompletedNCT03178591Phase 4
- A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.CompletedNCT03169959Phase 1
- Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy SubjectsCompletedNCT03138356Phase 1
- Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive SubjectsCompletedNCT03089333Phase 4
- Pilot Study to Explore the Efficacy of DAPAglifozin as add-on to Closed-loop Control in Patients With Type 1 DiabetesCompletedNCT02987738Phase 1
- Dapagliflozin + Saxagliptin in a Basal-bolus Insulin TreatmentTerminatedNCT02965443Phase 4
- Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?CompletedNCT02956811Phase 4
- Effect of Anti-diabetic Drugs on Glycemic VariabilityCompletedNCT02925559Phase 4
- Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial ArteryCompletedNCT02919345Phase 4
- Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.Status unknownNCT02919059Phase 4
- Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.TerminatedNCT02887677Phase 4
- HbA1c Variability in Type II DiabetesActive, not recruitingNCT02879409Not applicable
- Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR SpectroscopyCompletedNCT02798757Phase 4
- A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 DiabetesCompletedNCT02765204Phase 4
- Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic PatientsCompletedNCT02751398Phase 4
- Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2Status unknownNCT02719756Phase 4
- Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActiceWithdrawnNCT02719132Phase 4
- The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetesCompletedNCT02695810Phase 2
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes PatientsCompletedNCT02616666Phase 4
- Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to GliclazideCompletedNCT02610088Phase 4
- Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial EffectsCompletedNCT02585804Phase 4
- Dapagliflozin on Hyperlipidemia and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study)Status unknownNCT02577159Phase 4
- Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy MetabolismStatus unknownNCT02558270Phase 2
- Effect of Dapagliflozine on Systemic and Renal Endothelial FunctionStatus unknownNCT02501616Phase 4
- Effect of Dapagliflozin on Glycemic VariabilityCompletedNCT02459353Phase 4
- Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta CellCompletedNCT02420392Not applicable
- Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and DiabetesCompletedNCT02397421Phase 4
- Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium ContentCompletedNCT02383238Phase 3
- Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 DiabetesStatus unknownNCT02372955Phase 4
- Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination TherapyCompletedNCT02338921Phase 4
- The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic PatientsCompletedNCT02327039Phase 4
- Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin in Adolescents and Adults With Type 1 DiabetesCompletedNCT02325206Phase 1
- Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body WeightCompletedNCT02313220Phase 2
- Glucose Control During Glucocorticoid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseCompletedNCT02253121Phase 4
- Dapagliflozin in Type 1 DiabetesCompletedNCT02211742Phase 4
- Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)CompletedNCT02060201Phase 1
- A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy VolunteersCompletedNCT01877889Phase 1
- Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise AloneSuspendedNCT01257412Phase 3
- Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)CompletedNCT01165268Phase 1
- Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy VolunteersCompletedNCT01156246Phase 1
- Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy SubjectsCompletedNCT01135446Phase 1
- A Study to to Assess the Effect of Dapagliflozin When Administered Once a Day Versus Twice a Day on Blood GlucoseCompletedNCT01072578Phase 1
- Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy SubjectsTerminatedNCT01068756Phase 1
- A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate TabletsCompletedNCT01055691Phase 1
- Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus PatientsCompletedNCT01055652Phase 1
- Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy SubjectsCompletedNCT00930865Phase 1
- Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy SubjectsCompletedNCT00908271Phase 1
- Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy SubjectsCompletedNCT00904176Phase 1
- Pharmacokinetic Drug Interaction Study of Dapagliflozin and Glimepiride or Sitagliptin in Healthy SubjectsCompletedNCT00842556Phase 1
- Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy SubjectsCompletedNCT00839683Phase 1
- Renal Mechanism of Action/Splay vs. TmGTerminatedNCT00726505Phase 1
- Effects of Single Oral Dose Dapagliflozin QT StudyCompletedNCT00688493Phase 1
- Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy SubjectsCompletedNCT00562250Phase 1
- Renal Impairment in Type 2 Diabetic SubjectsCompletedNCT00554450Phase 1
- Drug Interaction With MetforminCompletedNCT00546741Phase 1
- Phase I Multiple-Ascending Dose (Japan)CompletedNCT00538174Phase 1
- A Trial of BMS-512148 in Patients With Type 2 Diabetes MellitusCompletedNCT00263276Phase 2
- A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic SubjectsCompletedNCT00162305Phase 2